The DYNC2H1 Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Huh-7 human hepatocellular carcinoma cell line. This product provides a loss-of-function model for DYNC2H1, the gene encoding the heavy chain of cytoplasmic dynein-2, an essential motor for retrograde intraflagellar transport. The polyclonal nature of this population offers a genetically heterogeneous knockout background that can be employed for population-level studies of cilium-dependent signaling without the clonal selection artifacts often associated with single-cell-derived lines. Scientists can utilize this knockout pool to interrogate ciliary transport mechanisms and hedgehog pathway activation in a liver cancer context.
The parental Huh-7 cell line was originally established from a well-differentiated human hepatocellular carcinoma and is widely used as an in vitro model for liver cancer biology and hepatocyte function. Huh-7 cells retain many characteristics of primary hepatocytes, including expression of liver-specific metabolic enzymes and the ability to form polarized epithelial monolayers. Their tumorigenic origin and epithelial nature make them a suitable host for studying how defects in primary cilia contribute to oncogenic signaling, drug resistance, and metastatic behavior. Moreover, Huh-7 cells are known to form primary cilia under defined culture conditions, providing a relevant platform for investigating ciliary assembly and disassembly dynamics in a hepatic cancer setting.
DYNC2H1 encodes a subunit of the cytoplasmic dynein-2 complex that functions as the retrograde motor for intraflagellar transport (IFT). This motor drives the movement of IFT particles and ciliary building blocks from the ciliary tip back to the cell body, a process essential for ciliary assembly and maintenance. DYNC2H1 interacts with multiple IFT components including IFT88, IFT140, WDR34, WDR60, and DYNC2LI1, and its activity is critical for proper ciliogenesis. Disruption of DYNC2H1 leads to impaired retrograde transport, causing ciliary shortening, accumulation of IFT proteins at the tip, and defective hedgehog signal transduction. In the hedgehog pathway, the primary cilium orchestrates the processing of GLI transcription factors; loss of DYNC2H1 disrupts the regulated proteolysis of GLI3 and activation of GLI2, resulting in attenuated expression of hedgehog target genes such as GLI1 and PTCH1. Additionally, DYNC2H1 expression is controlled by ciliogenic transcription factors including RFX family members and FOXJ1, linking its regulation to broader ciliary gene expression programs.
In the liver cancer context, the role of primary cilia and hedgehog signaling is complex and context-dependent. Huh-7 cells, derived from hepatocytes, are known to exhibit cilia-dependent signaling that can influence cell proliferation, migration, and epithelial-mesenchymal transition. Loss of DYNC2H1 in Huh-7 cells may reveal how ciliary dysfunction affects hepatic tumor cell behavior, potentially altering responses to mitogenic stimuli or chemotherapeutic agents. This model can be used to dissect the contribution of ciliary hedgehog signaling to hepatocellular carcinoma progression, as aberrant GLI activation has been implicated in liver tumorigenesis. Furthermore, because DYNC2H1 mutations are associated with skeletal ciliopathies, this knockout platform allows investigation of ciliary signaling pathways that may be conserved between hepatic and skeletal tissues.
This polyclonal DYNC2H1 knockout product is suitable for a range of experimental applications including ciliopathy disease modeling, hedgehog signaling studies, and primary cilia biology in liver cancer. Representative assays include immunofluorescence staining for ciliary markers such as ARL13B and acetylated tubulin to quantify ciliation frequency and length, western blotting to assess hedgehog pathway protein levels, and GLI-luciferase reporter assays to measure pathway activity. RT-qPCR can be used to monitor expression changes of hedgehog target genes like GLI1 and PTCH1, while cell migration assays may reveal functional consequences of ciliary loss on hepatocellular carcinoma cell motility. For further details or to discuss custom applications, please contact Ascent Research.
